277 related articles for article (PubMed ID: 24518087)
21. A pilot characterization of human lung NSCLC by protein pathway activation mapping.
Zupa A; Improta G; Silvestri A; Pin E; Deng J; Aieta M; Musto P; Nitti D; Mammano E; Liotta L; Belluco C; Wulfkuhle J; Petricoin E
J Thorac Oncol; 2012 Dec; 7(12):1755-1766. PubMed ID: 23154546
[TBL] [Abstract][Full Text] [Related]
22. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.
Loo PS; Thomas SC; Nicolson MC; Fyfe MN; Kerr KM
J Thorac Oncol; 2010 Apr; 5(4):442-7. PubMed ID: 20195168
[TBL] [Abstract][Full Text] [Related]
23. Expression of tumor necrosis factor receptor-associated factor 6 in lung cancer tissues.
Zhang XL; Dang YW; Li P; Rong MH; Hou XX; Luo DZ; Chen G
Asian Pac J Cancer Prev; 2014; 15(24):10591-6. PubMed ID: 25605144
[TBL] [Abstract][Full Text] [Related]
24. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer.
Han KY; Gu X; Wang HR; Liu D; Lv FZ; Li JN
Tumour Biol; 2013 Apr; 34(2):821-5. PubMed ID: 23229099
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of muscarinic receptor 3 promotes metastasis and predicts poor prognosis in non-small-cell lung cancer.
Lin G; Sun L; Wang R; Guo Y; Xie C
J Thorac Oncol; 2014 Feb; 9(2):170-8. PubMed ID: 24419413
[TBL] [Abstract][Full Text] [Related]
27. Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer.
Zhou Y; Wan C; Liu Y; Lv L; Chen B; Ni R; Huang Y; Li Y; Zheng X; Yang D; Mao G; Xue Q
Pathol Oncol Res; 2014 Jul; 20(3):549-56. PubMed ID: 24414991
[TBL] [Abstract][Full Text] [Related]
28. Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters.
Bircan A; Bircan S; Kapucuoglu N; Songur N; Ozturk O; Akkaya A
Pathol Oncol Res; 2010 Dec; 16(4):553-61. PubMed ID: 20349288
[TBL] [Abstract][Full Text] [Related]
29. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
30. Pentraxin-3 as a prognostic marker in patients with small-cell lung cancer.
Liu C; Yao Y; Wang W
Med Oncol; 2014 Oct; 31(10):207. PubMed ID: 25178940
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC).
Liu YZ; Jiang YY; Hao JJ; Lu SS; Zhang TT; Shang L; Cao J; Song X; Wang BS; Cai Y; Zhan QM; Wang MR
Lung Cancer; 2012 Jul; 77(1):176-82. PubMed ID: 22456526
[TBL] [Abstract][Full Text] [Related]
32. [Clinicopathological and prognostic significance of ERα and ERβ expression in lung carcinomas: a tissue microarray study].
Yang X; Xue LY; Liu Y; Guo L; Wen P; Lin DM
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):678-83. PubMed ID: 24332055
[TBL] [Abstract][Full Text] [Related]
33. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.
Sigel CS; Moreira AL; Travis WD; Zakowski MF; Thornton RH; Riely GJ; Rekhtman N
J Thorac Oncol; 2011 Nov; 6(11):1849-56. PubMed ID: 21841504
[TBL] [Abstract][Full Text] [Related]
34. High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients.
Wei LX; Zhou RS; Xu HF; Wang JY; Yuan MH
Tumour Biol; 2013 Apr; 34(2):941-6. PubMed ID: 23264086
[TBL] [Abstract][Full Text] [Related]
35. The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs.
Micke P; Mattsson JS; Djureinovic D; Nodin B; Jirström K; Tran L; Jönsson P; Planck M; Botling J; Brunnström H
J Thorac Oncol; 2016 Jun; 11(6):862-72. PubMed ID: 26872818
[TBL] [Abstract][Full Text] [Related]
36. Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer.
Zhang T; Yu TT; Zhang DM; Hou XM; Liu XJ; Zhao D; Shan L
Med Oncol; 2014 May; 31(5):963. PubMed ID: 24748406
[TBL] [Abstract][Full Text] [Related]
37. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of phosphorylated mTOR/RPS6KB1 in non- small cell lung cancer.
Zhang Y; Ni HJ; Cheng DY
Asian Pac J Cancer Prev; 2013; 14(6):3725-8. PubMed ID: 23886172
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of fibroblast activation protein-α in non-small cell lung cancer after curative resection: a new predictor for prognosis.
Liao Y; Ni Y; He R; Liu W; Du J
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1523-8. PubMed ID: 23835897
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
